drakky-logo

HIV Treatment Guidelines

HIV Treatment Guidelines

Diagnosis and Monitoring

HIV Testing

HIV tests form a vital part in diagnosing and managing HIV. Recommended for individuals vulnerable to HIV, as well as expecting mothers and newborns, there are various types of tests like antibody, rapid and nucleic acid tests. These tests function to locate either antibodies produced by the immune system in counter to HIV infection or the genetic material of the virus itself. Though highly accurate, some tests might fail to detect HIV during a certain window period after infection, implying necessity for routine testing at times. It is confidential and can be conducted at trusted healthcare facilities, community-based organizations, or via self-testing kits available in specific places. Early detection via testing allows immediate commencement of required treatment and care.

CD4 Count Monitoring

CD4 count tracking is a significant part of HIV care and an assurance of effective disease management. Serving as an indicator of the immune system's health and status of HIV progression, regular CD4 count monitoring facilitates healthcare providers in making educated decisions on initiating or fine-tuning Antiretroviral Therapy (ART). The frequency of CD4 monitoring is based on the individual's CD4 count and overall health. People with higher CD4 counts might need fewer tests, while those with lower counts or those showing symptoms might need more regular tests. Continued CD4 count monitoring is valuable not only to decide the apt time to initiate ART, but also to supervise effectiveness of treatment and progress of the disease. It's significant for health-care providers to define the importance of CD4 count monitoring to HIV patients to ensure sustained engagement in long-term care.

Viral Load Monitoring

Viral load monitoring is a salient feature of HIV care and management. It encompasses measuring the amount of HIV genetic material (RNA) in the patient's bloodstream and gauging the effectiveness of Antiretroviral Therapy (ART). Regular checks allow healthcare providers to keep a track of viral suppression levels in patients. Regular monitoring helps doctors measure the response to treatment and tweak the therapy as necessary. Viral load testing is suggested at the time of HIV diagnosis, before starting ART and periodically during the treatment to ensure suppression of the virus. A viral load below 200 copies/mL is considered undetectable, and indicates successful treatment. It's important for patients to adhere to their medication plan to reach and uphold a low viral load, as greater loads might insinuate treatment failure or the emergence of drug resistance. Regular monitoring aids in identifying those needing additional interventions such as adherence support or treatment alteration to optimize results.

Resistance Testing

The critical role of resistance testing in managing HIV treatment cannot be understated. It uses the genetic analysis of the virus to determine its susceptibility to various antiretroviral drugs. It's typically done in individuals who have undergone treatment failure or who are initiating Antiretroviral Therapy (ART) for the first time. Resistance testing identifies specific mutations in the viral genes, providing crucial information about which drugs are likely to be effective and which may be less potent. This guidance helps healthcare providers select the most suitable ART regimen. It should be noted that resistance testing is generally performed selectively in certain clinical scenarios to maximize treatment outcomes.

Antiretroviral Therapy (ART)

Initial ART Regimens

The initiation of ART involves a crucial selection process aligned with the individual characteristics of the patient. The regimen must be formulated based on factors such as the patient's overall health status, any existing conditions, potential drug interactions, and drug resistance results if they have been previously determined. It is therefore advised to opt for a judicious mix of three antiretroviral drugs from various classifications. Typically**, two nucleoside reverse transcriptase inhibitors (NRTIs), coupled with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase strand transfer inhibitor (INSTI)**, form the backbone of any ART regimen. Factors such as potential side effects, dosing convenience, and patient preference should be factored in when selecting specifics within any class. An apt initial ART regimen should strike a balance between the benefits and potential risks, with the goal to maximize viral suppression and prevent the development of resistance.

hiv treatment guidelines

Switching ART Regimens

The term 'switching ART regimens' refers to the necessary change in the initial ART regimen because of drug resistance, unbearable side effects, or the necessity to streamline the current regimen. Prior to making a change, it is essential to appraise the patient's viral load and resistance profile. The guiding principles behind switching should be to enhance viral suppression and long-term treatment effectiveness while reducing any toxic implications. Important considerations include patients' past treatments, existing ailments, potential drug-drug interactions, and personal preferences. A thorough examination following the switch is vital to determining the effectiveness and tolerance level of the new regimen. Following up-to-date guidelines and seeking expert advice are invaluable for managing the switch optimally.

Adherence to ART

Precise adherence to the prescribed ART regimen plays a pivotal role in the successful management of HIV. It is key in not only reducing viral replication and arresting disease progression but also in avoiding the emergence of drug-resistant strains. Not adhering to the ART regime may result in severe outcomes, such as treatment failure and increased morbidity and mortality. Adherence can be impacted by certain factors, including medication side effects, complexity of dosage, psychosocial concerns, and limitations in healthcare accessibility. Combatting these factors can significantly enhance adherence, which can be further achieved via methods like patient education, drug regimen simplification, reminder systems, providing support, and regular viral load monitoring. Optimal adherence is a continuous commitment and a collaborative effort between patients and their healthcare providers, with the aim of maximizing treatment outcomes.

ART in Special Populations

Special populations, such as pregnant women, children, adolescents, the elderly, individuals with co-existing ailments, and those with specific genetic variations require particular care when commencing or modifying an ART regimen. The chosen regimen should take into account maternal and fetus factors for pregnancy cases, and age and formulation appropriate for pediatric patients. Similarly, addressing psychosocial issues and management adherence are crucial for adolescent patients. Elderly patients may need additional measures due to physiological changes affecting drug metabolism. Also, patients with coexisting diseases like liver or kidney conditions may require tailored ART regimens considering possible drug interactions and potential side effects. Furthermore, genetic variations influencing drug effectiveness may play a role in selecting and dosing ART medications. It underlines the need for healthcare providers to consider these unique factors to offer the safest and most effective ART regimen for each case.

ART Side Effects and Management

ART can potentially lead to various side effects; while some of them are typical and temporary, such as nausea and fatigue, more serious complications like liver problems and changes in blood sugar levels could also emerge. People receiving ART should stay informed of these potential side effects and immediately report any worrying symptoms encountered to healthcare providers. Efficient management strategies include adjusting the ART regimen, giving supportive drugs to mitigate symptoms, or treating any underlying conditions. Regular monitoring and ongoing communication with healthcare providers help ensure identifying and managing side effects swiftly.

Bibliography

  1. Health Organization, W. o. r. l. d. (2021). Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. (https://apps.who.int/iris/bitstream/handle/10665/340190/9789240022232-eng.pdf)

  2. Renju, J., Rice, B., Songo, J., Hassan, F., Chimukuche, R. S., McLean, E., ... & Wringe, A. (2021). Influence of evolving HIV treatment guidance on CD4 counts and viral load monitoring: A mixed-methods study in three African countries. Global public health, 16(2), 288-304. (https://www.tandfonline.com/doi/pdf/10.1080/17441692.2020.1805785)

  3. Saag, M. S. (2021). HIV infection---screening, diagnosis, and treatment. New England Journal of Medicine. (https://www.nejm.org/doi/full/10.1056/NEJMcp1915826)

  4. Health Organization, W. o. r. l. d. (2020). Module for assessing and strengthening the quality of viral load testing data within HIV programmes and patient monitoring systems: implementation tool. (https://apps.who.int/iris/bitstream/handle/10665/336252/9789240010376-eng.pdf)

  5. Villa, G., Abdullahi, A., Owusu, D., Smith, C., Azumah, M., Sayeed, L., ... & Geretti, A. M. (2020). Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa. EClinicalMedicine, 18. (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30236-6/fulltext)

  6. Qiu, S., Zhao, H., Jiang, N., Wang, Z., Liu, L., An, Y., ... & Fortino, G. (2022). Multi-sensor information fusion based on machine learning for real applications in human activity recognition: State-of-the-art and research challenges. Information Fusion, 80, 241-265. (https://www.sciencedirect.com/science/article/pii/S1566253521002311)

  7. Cinelli, M., Kadziński, M., Gonzalez, M., & Słowiński, R. (2020). How to support the application of multiple criteria decision analysis? Let us start with a comprehensive taxonomy. Omega. (https://www.sciencedirect.com/science/article/pii/S0305048319310710)

  8. Musinguzi, N., Kidoguchi, L., Mugo, N. R., Ngure, K., Katabira, E., Celum, C. L., ... & Partners Demonstration Project Team. (2020). Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the "PrEP as a bridge to ART" strategy. BMC public health, 20, 1-10. (https://link.springer.com/article/10.1186/s12889-020-09712-3)

  9. Morillo-Verdugo, R., Polo, R., Knobel, H., & PNS-GESIDA-SEFH expert group. (2020). Consensus document on enhancing medication adherence in patients with the human immunodeficiency virus receiving antiretroviral therapy. Farmacia Hospitalaria, 44(4), 163-173. (https://www.sciencedirect.com/science/article/pii/S1130634323003653)

  10. Spinelli, M. A., Haberer, J. E., Chai, P. R., Castillo-Mancilla, J., Anderson, P. L., & Gandhi, M. (2020). Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Current HIV/AIDS Reports, 17, 301-314. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363551/)